Logopenic progressive aphasia

Logopenic progressive aphasia (LPA), also known as logopenic variant primary progressive aphasia (lvPPA), is a neurodegenerative disorder that primarily affects the language network of the brain. It is one of three recognized clinical variants of primary progressive aphasia (PPA), alongside the semantic and nonfluent/agrammatic variants. LPA is characterized by progressive difficulty with word-finding (anomia), impaired repetition of sentences and phrases, and frequent pauses in spontaneous speech as patients search for words. Unlike other PPA variants, grammar and motor speech production are relatively preserved in the early stages, and single-word comprehension typically remains intact initially. The underlying pathology in the majority of LPA cases is Alzheimer disease, with accumulation of amyloid plaques and neurofibrillary tangles predominantly affecting the left temporoparietal junction and posterior perisylvian regions of the brain. This distinguishes LPA from the other PPA variants, which are more commonly associated with frontotemporal lobar degeneration pathology. As the disease progresses, patients may develop additional cognitive deficits beyond language, including impairments in episodic memory, visuospatial abilities, and executive function, eventually leading to broader dementia. Onset typically occurs in the late fifties to mid-sixties, though it can present earlier or later. There is currently no cure or disease-modifying treatment specifically approved for LPA. Management is primarily supportive and includes speech-language therapy aimed at maintaining communication abilities for as long as possible, compensatory communication strategies, and caregiver education. Given the frequent underlying Alzheimer disease pathology, cholinesterase inhibitors and memantine may be considered, though evidence for their efficacy specifically in LPA is limited. Emerging amyloid-targeted therapies for Alzheimer disease may hold future promise for patients with biomarker-confirmed amyloid pathology.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Logopenic progressive aphasia